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Abstract
Background:  Bacterial  resistance  may  hamper  the  antimicrobial  management  of  acute  gastroen-
teritis. Bacterial  susceptibility  to  rifaximin,  an  antibiotic  that  achieves  high  fecal  concentrations
(up to  8,000  g/g),  has  not  been  evaluated  in  Mexico.
Objective:  To  determine  the  susceptibility  to  rifaximin  and  other  antimicrobial  agents  of
enteropathogenic  bacteria  isolated  from  patients  with  acute  gastroenteritis  in  Mexico.
Material  and  methods:  Bacterial  strains  were  analyzed  in  stool  samples  from  1,000  patients
with diagnosis  of  acute  gastroenteritis.  The  susceptibility  to  rifaximin  (RIF)  was  tested  by
microdilution  (<  100,  <  200,  <  400  and  <  800  g/ml)  and  susceptibility  to  chloramphenicol  (CHL),
trimethoprim-sulfamethoxazole  (T-S),  neomycin  (NEO),  furazolidone  (FUR),  fosfomycin  (FOS),
ampicillin (AMP)  and  ciproﬂoxacin  (CIP)  was  tested  by  agar  diffusion  at  the  concentrations
recommended  by  the  Clinical  &  Laboratory  Standards  Institute  and  the  American  Society  for
Microbiology.
Results: Isolated  bacteria  were:  enteropathogenic  Escherichia  coli  (E.  coli)  (EPEC)  531,  Shigella
120, non-Typhi  Salmonella  117,  Aeromonas  spp. 80,  enterotoxigenic  E.  coli  (ETEC)  54,  Yersinia
enterocolitica  20,  Campylobacter  jejuni  20,  Vibrio  spp. 20,  Plesiomonas  shigelloides  20,  and
enterohemorrhagic  E.  coli  (EHEC  0:157)  18.  The  overall  cumulative  susceptibility  to  RIF  at
<100, <200,  <400,  and  <800  g/ml  was  70.6,  90.8,  99.3,  and  100%,  respectively.  The  overall
susceptibility  to  each  antibiotic  was:  AMP  32.2%,  T-S  53.6%,  NEO  54.1%,  FUR  64.7%,  CIP  67.3%,
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CLO  73%,  and  FOS  81.3%.  The  susceptibility  to  RIF  <400  and  RIF  <800  g/ml  was  signiﬁcantly
greater than  with  the  other  antibiotics  (p  <  0.001).
Conclusions:  Resistance  of  enteropathogenic  bacteria  to  various  antibiotics  used  in  gastroin-
testinal infections  is  high.  Rifaximin  was  active  against  99-100%  of  these  enteropathogens  at
reachable  concentrations  in  the  intestine  with  the  recommended  dose.
© 2015  Asociación  Mexicana  de  Gastroenterología.  Published  by  Masson  Doyma  México  S.A.
This is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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Susceptibilidad  de  las  bacterias  aisladas  de  infecciones  gastrointestinales  agudas  a  la
rifaximina  y  otros  agentes  antimicrobianos  en  México
Resumen
Antecedentes:  La  resistencia  bacteriana  puede  diﬁcultar  el  tratamiento  antimicrobiano  de  las
gastroenteritis  agudas.  La  susceptibilidad  bacteriana  de  los  enteropatógenos  a  la  rifaximina,
un antibiótico  que  alcanza  altas  concentraciones  fecales  (hasta  8,000  g/g)  no  se  ha  evaluado
en México.
Objetivos:  Determinar  la  susceptibilidad  a  rifaximina  y  a  otros  antimicrobianos  de  bacterias
enteropatógenas  aisladas  de  pacientes  con  gastroenteritis  aguda  en  México.
Material  y  métodos:  Se  analizaron  las  cepas  bacterianas  en  las  heces  de  1,000  pacientes
con diagnóstico  de  gastroenteritis  aguda.  Se  probó  la  susceptibilidad  a  la  rifaximina  (RIF)
con microdilución  (<  100,  <  200,  <  400  y  <  800  g/ml),  la  susceptibilidad  a  cloranfenicol
(CLO), trimetoprim-sulfametoxazol  (T-S),  neomicina  (NEO),  furazolidona  (FUR),  fosfomicina
(FOS), ampicilina  (AMP)  y  ciproﬂoxacino  (CIP)  se  probó  por  difusión-agar  a  las  concentraciones
recomendadas  por  CLSI  y  ASM.
Resultados:  Las  bacterias  aisladas  fueron:  Escherichia  coli  (E.  coli)  enteropatógena  (EPEC)  531,
Shigella 120,  Salmonella  no-typhi  117,  Aeromonas  spp.  80,  E.  coli  enterotoxigénica  54,  Yersinia
enterocolitica  20,  Campylobacter  jejuni  20,  Vibrio  spp.  20,  Pleisiomonas  shigelloides  20  y  E.  coli
enterohemorrágica  (EHEC  0:157)  18.  La  susceptibilidad  global  acumulada  a  RIF  <  100,  <  200,
< 400,  <  800  g/ml  fue  del  70.6,  el  90.8,  el  99.3  y  el  100%,  respectivamente.  La  susceptibilidad
global a  cada  antibiótico  fue:  AMP  32.2%,  T-S  53.6%,  NEO  54.1%,  FUR  64.7%,  CIP  67.3%,  CLO
73%, FOS  81.3%.  La  susceptibilidad  a  RIF  <  400  y  <  800  g/ml  fue  signiﬁcativamente  mayor  que
con los  otros  antimicrobianos  (p  <  0.001).
Conclusiones:  La  resistencia  de  las  bacterias  enteropatógenas  a  antimicrobianos  utilizados  en
gastroenteritis  es  alta.  La  rifaximina  fue  activa  contra  el  99-100%  de  las  bacterias  en  concen-
traciones  alcanzables  en  el  contenido  intestinal  con  las  dosis  recomendadas.
© 2015  Asociación  Mexicana  de  Gastroenterología.  Publicado  por  Masson  Doyma  México  S.A.
Este es  un  artículo  Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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cute  diarrhea  is  an  important  health  problem,  mainly  in
he  developing  countries.  Despite  the  decrease  in  mortal-
ty  rates  from  this  disease  in  the  last  decade  in  various
ountries,  including  Mexico1--3,  acute  gastroenteritis  contin-
es  to  be  a  health  problem  due  to  its  high  morbidity.  In
exico,  it  is  the  second  most  common  infectious  disease,
nly  preceded  by  respiratory  diseases,  with  more  than  5
illion  new  cases  per  year4.
Despite  the  presence  of  certain  clinical  signs,  it  is  dif-
cult  to  determine  the  causal  agent  of  acute  diarrhea
n  a  patient  based  solely  on  clinical  ﬁndings.  Acute  gas-
roenteritis  is  often  due  to  a  viral  infection,  especially  in
hildren  under  5  years  of  age1,  whereas  bacterial  infec-
ion  is  more  habitual  in  older  children  and  adults.  The
a
p
a
iost  frequently  detected  enteropathogenic  bacteria  in
atients  with  endemic  gastroenteritis  are  Escherichia  coli
E.  coli) (EPEC,  EIEC,  EHEC,  ETEC),  Campylobacter
ejuni  (C.  jejuni), Shigella  spp,  Salmonella  spp,  Yersinia
nterocolitica  (Y.  enterocolitica)5--8,  and  less  frequently,
eromonas  spp,  Vibrios  spp9--12, and  Pleisomonas  shigeloides
P.  shigeloides)13--15.  The  number  of  cases  vary  in  relation  to
eographic  region,  patient  age,  and  the  season  of  the  year
n  which  the  study  was  conducted.
The  aims  of  therapeutic  management  of  patients
ffected  with  gastroenteritis  are  to  preserve  life,  relieve
ymptoms,  prevent  complications,  cut  the  disease  short,
nd  prevent  the  spread  of  the  pathogenic  agents  to  the
opulation.  Oral  rehydration  is  the  standard  treatment  in
cute  gastroenteritis  and  antimicrobial  agents  are  indicated
n  severe  or  prolonged  cases,  when  shigellosis  or  cholera
al  in
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ASusceptibility  of  bacteria  isolated  from  acute  gastrointestin
are  suspected,  or  when  the  pathogen  is  known,  in  order
to  prevent  contagion16.  However,  in  daily  clinical  practice,
when  the  result  of  the  stool  culture  is  reported,  the  patient
is  already  recovering  or  the  treatment  is  delayed.  Know-
ing  the  susceptibility  of  the  bacteria  causing  a  syndrome
to  the  antimicrobial  agents  is  important  in  2  aspects:  one
is  the  early  therapeutic  approach,  out  of  empirical  neces-
sity,  and  the  other  is  the  epidemiologic  surveillance  of
bacterial  resistance  that  is  useful  for  taking  measures  to
prevent  it.
The  empirical  use  of  antimicrobials  can  be  inefﬁcient
due  to  the  emergence  of  bacterial  resistance.  Therefore
the  possible  therapeutic  regimens  should  be  frequently
updated,  taking  the  pattern  of  regional  resistance  into
account17--20.  Some  clinical  studies  indicate  that  quinolones
are  superior  to  other  antibiotics  or  to  placebo  in  the  empir-
ical  treatment  of  adult  patients  with  diarrhea17,20--22.  Other
antimicrobial  drugs,  such  as  ampicillin  (AMP),  trimethoprim-
sulfamethoxazole  (T-S),  chloramphenicol  (CHL),  furazoli-
done  (FUR),  and  non-absorbable  antibiotics,  such  as
neomycin  and  recently  rifaximin  (RIF),  have  been  used  in
children,  in  whom  quinolones  are  not  indicated,  and  also
in  adults17,23--25.  Nevertheless,  recent  data  on  the  bacterial
susceptibility  to  these  antimicrobial  agents  is  not  available
in  Mexico.  RIF  is  a  semisynthetic  antibiotic  derived  from
broad  spectrum  rifamycin  S  that  inhibits  the  synthesis  of
bacterial  RNA,  is  not  absorbable  when  taken  orally,  and
reaches  a  very  high  concentration  in  the  intestinal  lumen
(∼8,000  g/g  of  feces).  It  has  excellent  bactericide  activ-
ity  on  enteropathogenic  microorganisms  and  does  not  cause
important  alterations  in  the  gut  microbiota26.The  aim  of  this  study  was  to  investigate  the  susceptibil-
ity  of  the  acute  gastroenteritis-causing  bacteria  to  rifaximin
and  the  most  widely  used  antibiotics  in  the  treatment  of
gastrointestinal  infections  in  Mexico.
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Table  1  Bacteria  isolated  from  1,000  patients  diagnosed  with  ac
Bacteria  Number  Serotypes  invo
Enteropathogenic
E.  coli  group
A,B,  and  C
531  O127:B8,  O111
O119:B4,  O128
O142:B86,  O11
should corresp
Enterotoxigenic  (LT)  E.  coli  54  Only  thermolab
Enterohemorrhagic  E.  coli  18  Only  O:157  ser
Shigella  dysenteriae  54  All  the  serotyp
Shigella ﬂexneri  24  All  the  serotyp
Shigella boydii  27  All  the  serotyp
Shigella sonnei  15  All  the  serotyp
Salmonella Group  A  24  Most  likely  spe
Salmonella  Group  B  21  Most  likely  spe
Salmonella  Group  C1  24  Most  likely  spe
Salmonella  Group  C2  24  Most  likely  spe
Salmonella  Group  D  24  Most  likely  spe
Vibrio spp.  20  --
Yersinia  enterocolitica 20  --
Campylobacter  jejuni 20  --
Pleisomonas  shigeloides  20  --
Aeromonas  80  --fections  5
ethods
acterial  isolations
acterial  strains  obtained  from  the  stool  samples  of
,000  patients  diagnosed  with  gastroenteritis  or  acute  diar-
hea  were  analyzed  in  10  hospital  laboratories  in  Mexico
ity  that  attend  to  hospitalized  patients  and  outpatients.
he  strains  were  conserved  and  frozen  before  carrying  out
he  biochemical  identiﬁcation,  serology,  and  the  antimicro-
ial  susceptibility  test  in  milk  broth  and  soy  broth  with
lycerol  at  −70 ◦C;27 the  initial  primary  isolations  from  the
tool  samples  were  carried  out  at  each  particular  labora-
ory,  and  the  following  culture  media  were  used:  MacConkey
gar,  Sorbitol-MacConkey  Agar,  Salmonella  Shigella  Agar,
LD  Agar,  Campylobacter  Agar,  Yersinia  Agar,  TCBS  Agar,
rilliant  Green  Agar,  and  Tetrathionate  Broth28.
The  isolates  were  biochemically  identiﬁed  in  each
aboratory  using  AutoScan  4,  Walkaway  (MicroScan),  or
itek  2  (Biomeriux)  manual  and  automated  processes  and
ystems29--31 with  an  acceptance  probability  >  95%  in  the
dentiﬁcation;  the  typing  and  serologic  identiﬁcation  in
etermined  bacterial  species,  such  as  E.  coli,  Salmonella,
nd  Shigella,  were  then  performed  using  the  Bio-Rad32,
hadebact33,  Oxoid34, Sanoﬁ-Pasteur35,  ‘‘O’’  Beli36,  and
robac37 speciﬁc  antisera  and  agglutination  or  coagglutina-
ion  reagents.  The  detected  serogroups  and  serotypes  are
hown  in  Table  1.
ntimicrobial  agents  and  susceptibility  testsntimicrobial  susceptibility  testing  (AST)  was  done  through
he  agar  diffusion  method  (CHL,  T-S,  neomycin  [NEO],  FUR,
osfomycin  [FOS],  AMP,  and  ciproﬂoxacin  [CIP]),  and  by
ute  gastroenteritis  and  their  serotypes.
lved
:B4,  O55:B5,  O26:B6  and  other  serotypes
:B12,  O124:B17,  O86:B7,  O126:b16  and  other  serotypes
9:K90,  O124:B17,  O86:B7,  O126:B16  and  other  serotypes  that
ond  to:  O128:K73,  O44:K74,  O18:K77,  O20:K61,  and  O20:K84
ile  (TL)  toxin-producing  serotypes
otype
es  that  are  agglutinable  with  the  speciﬁc  antiserum
es  agglutinable  with  the  speciﬁc  antiserum
es  that  are  agglutinable  with  the  speciﬁc  antiserum
es  that  are  agglutinable  with  the  speciﬁc  antiserum
cies:  S.paratyphi
cies:  S.typhimurium
cies:  S.choleraesuis
cies:  S.newport
cies:  S.enteritidis
6 O.  Novoa-Farías  et  al.
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Figure  1  Overall  accumulated  susceptibility  of  the  isolated
bacteria  to  rifaximin.  In  the  1,000  strains,  RIF  was  tested  at
a concentration  of  100  g/ml.  The  bacteria  that  were  not
susceptible  at  that  concentration  were  successively  exposed
to concentrations  of  200  g/ml,  400  g/ml,  and  800  g/ml.  The
a
9
1
5
R
t
(
e
t
h
b
V
D
T 
icrodilution  (RIF)  following  the  recommendations  of  the
linical  &  Laboratory  Standards  Institute38 and  the  Amer-
can  Society  for  Microbiology39.  The  concentrations  of  the
ntibiotics  assayed  and  AST  conditions  were:  AMP  10  g/ml,
-S  1.25/23.75  g/ml,  CHL  30  g/ml,  CIP  5  g/ml,  FUR
00  g/ml,  NEO  30  g/ml,  FOS  50  g/ml.  RIF  was  tested  at
00  g/ml  and  the  strains  that  were  not  susceptible  at  this
oncentration  were  successively  exposed  to  concentrations
f  200  g/ml,  400  g/ml,  and  800  g/ml.  Susceptibility  to
IF  was  considered  at  a  minimal  inhibitory  concentration
MIC)  of  MIC100,  whereas  it  was  MIC90 for  the  other  antibi-
tics.
tatistical  analysis
acterial  susceptibility  to  RIF  was  compared  with  the  sus-
eptibility  to  the  other  antimicrobial  agents  with  the  Z  test
nd  statistical  signiﬁcance  was  set  at  a  p  <  0.05.  The  Statis-
ica  8.0  and  Stata  11  statistical  software  were  employed.
esults
he  stool  samples  from  511  men  and  489  women  were  ana-
yzed.  Sixty-ﬁve  percent  of  the  participants  were  above
0  years  of  age.  The  isolated  bacteria  were  E.  coli  603  (EPEC
31,  ETEC  54,  EHEC  18),  Shigella  120  (dysenteriae,  ﬂexneri,
oydii,  sonnei),  Salmonella  117  (paratyphi,  typhimurium,
holeraesuis,  newport,  enteritidis), Vibrio  spp.  20,  Y.  ente-
ocolitica  20,  C.  jejuni  20,  P.  shigeloides  20,  and  Aeromonas
pp.  80.
Overall  susceptibility  of  the  bacteria  to  the  different
oncentrations  of  RIF  (MIC100)  are  shown  in  Figure  1.  The
esults  of  accumulated  susceptibility  patterns  in  all  the
trains  assayed  were  at  <  100  g/ml:  70.6%;  at  <  200  g/ml:
0.8%;  at  <  400  g/ml:  99.3%;  and  at  <  800  g/ml:  100.0%.
able  2 shows  the  susceptibility  of  each  group  of  bacte-
ia  to  the  different  RIF  concentrations.  More  than  99%  of
he  strains  of  Shigella,  Salmonella,  Yersinia,  Campylobac-
er,  Vibrio,  Pleisiomonas, and  Aeromonas  were  susceptible
o  concentrations  <  100  or  <  200  g/ml,  whereas  11-15%  of
he  E.  coli  required  <  400  or  even  <  800  g/ml.
Overall  susceptibility  of  all  the  bacterial  species  to  each
ntibiotic  was:  RIF  (<  400  g/ml)  99.3%  and  (<  800  g/ml)
g
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Table  2  Susceptibility  of  the  bacteria  to  different  concentration
Bacteria  Number  <  100  g/ml  
EPEC  531  58.95  
ETEC 54  79.63  
EHEC 18  72.22  
Shigella 120  90.00  
Salmonella 117  67.52  
Yersinia 20  80.00  
Campylobacter  20  70.00  
Vibrio 20  100.00  
Plesiomonas 20  100.00  
Aeromonas 80  100.00  
All 1000  70.6  
Results expressed in % of susceptible strains.ccumulated  susceptible  strains  were  706  (<  100),  908  (<  200),
93 (<  400),  and  1,000  (<  800).
00%,  FOS  81.3%,  CHL  73.0%,  CIP  67.3%,  FUR  64.7%,  NEO
4.1%,  T-S  53.6%,  and  AMP  32.2%.  Overall  susceptibility  to
IF  with  <  400  and  <  800  g/ml  was  superior  (p  <  0.001)
o  the  overall  susceptibility  to  each  of  the  8  drugs  studied
ﬁg.  2).  This  was  also  true  in  the  majority  of  the  cases  in
ach  bacterial  group  alone.
Table  3  shows  the  susceptibility  of  each  bacterial  group
o  the  antibiotics  tested.
As  can  be  seen,  a  large  number  of  strains  show  a  very
igh  proportion  of  bacterial  resistance  to  NEO,  T-S,  and  AMP,
ut  Yersinia  continues  to  be  very  susceptible  to  AMP  (100%),
ibrio  to  T-S  (90%),  and  Campylobacter  to  NEO.
iscussion
he  prevalence  and  incidence  of  the  bacteria  that  cause
astroenteritis  worldwide  vary  according  to  the  type  of
opulation  studied,  the  geographic  location  of  the  study,
he  season  of  the  year  in  which  the  microbiologic  diag-
osis  is  made,  and  other  clinical  and  sociodemographic
s  of  rifaximin.
<  200  g/ml  <  400  g/ml  <  800  g/ml
25.61  14.69  0.75
7.41  7.41  5.56
16.67  11.11  --
10.00  --  --
31.62  0.85  --
20.00  --  --
30.00  --  --
--  --  --
--  --  --
--  --  --
20.2  8.5  0.7
Susceptibility  of  bacteria  isolated  from  acute  gastrointestinal  in
99.3
81.3
67.3
64.7
54.1 53.6
32.2
73
RIF  FOS  CHL  CIP  FUR  NEO T-S AMP
100
90
80
70
60
50
40
30
20
10
%
0
Figure  2  Overall  susceptibility  of  the  1,000  isolated  bacterial
strains  to  the  different  antibiotics.
Rifaximin  vs  the  other  antimicrobials  p  <  0.0001.
AMP:  ampicillin;  CHL:  chloramphenicol;  CIP:  ciproﬂoxacin;  FOS:
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efosfomycin;  FUR:  furazolidone;  NEO:  neomycin;  RIF:  rifaximin
(< 400  g/ml);  T-S:  trimethoprim-sulfamethoxazole.
characteristics  of  the  patients  studied6,40--42.  Even  though
ours  was  not  a  prevalence  study,  the  strains  were  collected
throughout  the  entire  year  of  2013  and  therefore  the  sea-
sonal  variations  were  not  inﬂuential.  The  frequency  of  the
strains  received  in  the  clinical  analysis  laboratories  was
reﬂected  and  the  dominating  ones  were  E.  coli,  Shigella,
Salmonella, and  Aeromonas.  These  data  coincide  with  other
reports  in  Mexico23,43,44.
Standards  for  deﬁning  susceptibility  or  bacterial  resis-
tance  have  been  published  for  the  majority  of  antibiotics38.
Nevertheless,  there  are  no  clinical  cut-off  points  for
rifamycins  against  enteropathogens,  although  a  value  of
≤  32  g/ml  of  rifaximin  was  applied  by  some  researchers  in
traveler’s  diarrhea45--47.  Bacterial  susceptibility  to  an  antibi-
otic  implies  that  the  isolations  are  inhibited  by  the  usually
achievable  concentration  of  the  antimicrobial  agent  at  the
infection  site  when  the  recommended  dose  is  used.  Fecal
concentrations  of  rifaximin  have  been  reported  of  up  to
8,000  g/g  (mean  7,961  g/g)  after  3  days  of  treatment  at
the  recommended  dose  of  800  mg/day,  and  there  were  still
mean  fecal  concentrations  of  3,266  g/g  3  days  after  the
f
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Table  3  Susceptibility  of  each  group  of  bacteria  to  the  antimicro
Group  of  bacteria  FOS  CHL  CIP  
EPEC  7.1  66.6  51.9  
ETEC 75.9  88.8  50.0  
EHEC 55.5  83.3  100  
Shigella 68.3  82.5  97.5  
Salmonella 77.8  64.1  89.7  
Yersinia 90.0  80.0  90.0  
Campylobacter  80.0  95.0  30.0  
Vibrio 90.0  80.0  100  
Plesiomonas  100  95.0  80.0  
Aeromonas 67.5  86.0  87.5  
All 81.3  73.0  67.3  
Results expressed in % of susceptible strains.fections  7
nd  of  the  therapy48. In  our  study,  we  evaluated  the  sus-
eptibility  to  rifaximin  at  4  concentrations:  <  100,  <  200,
 400,  and  <  800  g/ml.  The  general  susceptibility  observed
t  these  concentrations  implies  a  certain  bacterial  resis-
ance  to  rifaximin  at  concentrations  of  <  100  g/ml  that  was
vercome  at  higher  concentrations,  but  always  much  below
he  achievable  values  in  the  intestinal  lumen.  The  cut-off
oints  for  considering  bacteria  to  be  resistant  to  rifaximin
ave  been  established  at  32,  128,  or  even  256  g/ml46--49,
ut,  as  observed  in  our  study,  the  bacteria  resistant  to  lower
oncentrations  of  rifaximin  were  not  resistant  if  the  concen-
ration  of  the  antibiotic  was  increased  in  vitro. Finally,  99.3%
ere  susceptible  at  concentrations  <  400  g/ml  and  100%
t  concentrations  <  800  g/ml,  which  are  10-20  times  lower
han  the  mean  concentration  achieved  in  vivo  with  the  rec-
mmended  treatment.
The  concentrations  in  the  intestinal  lumen,  or  fecal  con-
entrations,  of  the  other  antimicrobial  agents  tested  in  the
resent  study  are  not  known,  so  the  internationally  rec-
mmended  concentrations  were  used  for  the  susceptibility
nalysis.  In  general,  the  bacteria  were  more  susceptible  to
ifaximin  than  to  the  other  antimicrobial  agents  tested  in  our
nalysis.  Recent  studies  with  enteropathogen  isolates  from
ravelers  coming  from  Latin  America  and  Asia  also  found  a
reater  proportion  of  bacteria  susceptible  to  rifaximin  than
o  other  antimicrobial  agents.  It  was  striking  that  the  C.
ejuni  strains  from  Asia  had  a  variable  resistance  to  rifax-
min,  whereas  those  from  Mexico  and  Guatemala  were  100%
usceptible46,47.  In  our  study,  the  C.  jejuni  strains  were
00%  susceptible  at  concentrations  of  <  100-200  g/ml.  Sev-
ral  strains  of  E.  coli  required  rifaximin  concentrations
reater  than  100  g/ml,  concurring  with  other  observations
n  bacteria  coming  from  Mexico50.
Rifaximin  has  a  broad  spectrum  of  susceptibility  that
ncludes  anaerobic  bacteria26,49.  Bacterial  resistance  is  very
ow  and  is  not  easily  induced51. In  addition,  Ouyang--Latimer
t  al.  compared  the  susceptibility  of  enteropathogenic
acteria  obtained  in  2006-2008  with  those  obtained
0  years  earlier  and  found  no  increase  in  the  MIC90 lev-
ls  for  rifaximin  in  any  of  the  organisms  analyzed46.  In
act,  the  normal  intestinal  bacteria  that  became  resis-
ant  to  100  g/ml  of  rifaximin  after  5  days  of  treatment
pontaneously  disappeared  from  the  stools  within  a  few
eeks52.
bials  tested.
FUR  NEO  T-S  AMP
66.4  48.5  49.1  27.6
77.7  53.7  50.0  29.6
50.0  61.1  16.6  16.6
47.5  46.6  27.5  48.3
64.1  52.1  74.4  50.4
80.0  30.0  2.5  100
100  100  30.0  45.0
90.0  70.0  90.0  55.0
85.0  90.0  90.0  20.0
50.0  80.0  78.7  20.0
64--7  54.1  53.6  32.2
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The  low  proportion  of  bacteria  that  are  susceptible  to
MP,  T-S,  neomycin,  FUR,  and  CIP,  from  32.2  to  67.3%  in  that
rder,  coincides  with  studies  conducted  in  other  regions  of
he  world53--56 and  can  be  explained  by  the  induction  of  bac-
erial  resistance  due  to  the  widespread  use  or  abuse  of  those
ntimicrobial  agents.  In  this  respect,  it  is  striking  that  CHL,
hich  conserves  an  acceptable  general  susceptibility  of  73%,
as  been  restricted,  after  its  widespread  use  in  Mexico,  to
reating  typhoid  fever  for  the  last  30  years.  And  compara-
ively,  in  our  study  we  introduced  the  test  of  susceptibility  to
OS.  This  antibiotic  is  used  very  little  in  Mexico,  and  mainly
n  urinary  infections.  The  general  susceptibility  of  FOS  was
reater  than  that  of  the  other  antimicrobial  agents,  just
elow  rifaximin.
Neomycin  is  a  poorly  absorbed  antibiotic  that  is  widely
sed  in  Mexico  and  does  not  require  a  prescription.  Accord-
ng  to  our  data,  it  is  clear  that  AMP,  T-S,  neomycin,  and
UR  would  not  be  good  therapeutic  options.  RIF  has  been
uccessfully  used  for  treating  acute  infectious  diarrhea  in
hildren  and  adults,  as  well  as  for  traveler’s  diarrhea,  with
xcellent  tolerance57--60.  RIF  would  appear  to  be  the  best
ption,  given  that  it  has  a  high  therapeutic  index,  com-
ining  high  efﬁcaciousness  with  a  low  frequency  of  adverse
ffects26.  Adverse  effects  are  frequently  attributed  to  other
ntibiotics,  especially  to  beta-lactams  and  T-S  mainly  due
o  allergies,  and  the  sulfonamides  and  CIP  are  known  to  be
eurotoxic61.
Treatment  with  antimicrobial  agents  is  a  valuable  tool
n  the  control  of  several  gastrointestinal  infections,  given
hat  the  length  of  time  and  intensity  of  the  disease  is
educed,  potentially  severe  complications  are  prevented,
nd  disease  transmission  is  decreased.  Unfortunately,  for
everal  decades,  enteropathogenic  bacteria  strains  have
een  selected  that  are  resistant  to  the  commonly  used
ntimicrobial  agents  and  to  those  that  once  were  considered
rst  choice62.  The  selection  and  dissemination  of  antimicro-
ial  resistance  among  the  different  bacterial  species  that
ause  gastroenteritis  is  a  growing  health  problem  that  com-
licates  the  therapeutic  management  of  the  severe  cases.
tudies  conducted  in  many  parts  of  the  world  have  revealed
n  important  increase  in  antimicrobial-resistant  bacteria  in
any  infectious  diseases,  including  gastroenteritis63,64. To
educe  the  appearance  of  antimicrobial-resistant  bacterial
trains,  it  would  seem  prudent  to  avoid  the  indiscriminate
se  of  antibiotics  in  cattle,  periodically  determine  local
acterial  resistance  patterns,  reduce  the  easy  access  to
ntimicrobial  drugs  (for  example:  prevent  self-medication
ith  antimicrobials),  and  strengthen  the  medical  education
n  this  topic.
Study  limitations.  The  stool  cultures  were  obtained
rom  10  laboratories  that  sent  positive  stool  cultures
ith  enteropathogen  bacteria  from  patients  diagnosed  with
cute  gastroenteritis  or  acute  diarrhea.  Therefore,  it  was
ot  possible  to  obtain  the  clinical  data,  such  as  the  length
f  time  of  symptom  progression,  stool  characteristics,  the
ymptoms  accompanying  the  diarrhea,  and  the  intensity
r  severity  of  the  clinical  symptoms  that  would  enable
heir  correlation  with  the  genus  and  species  of  the  bac-
erial  isolates.  The  stool  cultures  were  from  Mexico  City
nd  do  not  necessarily  reﬂect  those  from  the  rest  of  the
ountry.
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